Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL	B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm	Recruiting	Phase 2	2026-03-02		NCT07441993

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Tongren Hospital	60
Institute of Hematology & Blood Diseases Hospital, China	285

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Nantong University	Nantong	China	14
Beijing Tongren Hospital, Capital Medical University	Beijing	China	15
Hematology Hospital, Chinese Academy of Medical Sciences	Tianjin	China	2
Henan Cancer Hospital	Zhengzhou	China	98
Jiangsu Province People's Hospital	Nanjing	China	1
Nanfang Hospital, Southern Medical University	Guangzhou	China	33
Qilu Hospital of Shandong University	Jinan	China	68
Shandong Cancer Hospital & Institute	Jinan	China	4
Shandong Provincial Hospital	Jinan	China	24
The First Affiliated Hospital of Nanchang University	Nanchang	China	77
The First Bethune Hospital of Jilin University	Changchun	China	13
The Second Xiangya Hospital of Central South University	Changsha	China	39
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	20
Xiangyang Central Hospital	Xiangyang	China	14